SCHEMBL3324255

SCHEMBL3324255

Cc1ccc(OC[C@H]2CCCNC2)c(Oc2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.43
CHUK O15111 2/20 0.43
MAP2K1 Q02750 2/20 0.41
CHEK2 O96017 1/20 0.39
SLC6A2 P23975 3/20 0.39
SLC6A4 P31645 3/20 0.39
SLC6A3 Q01959 1/20 0.39
KDM1A O60341 1/20 0.39
IRAK4 Q9NWZ3 4/20 0.39
PIM1 P11309 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
CTSS P25774 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
JAK3 P52333 1/20 0.38
SYK P43405 2/20 0.37
KCNH2 Q12809 2/20 0.37
AURKB Q96GD4 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3323670 1.00 IKBKB (0.43) IKBKBCHUKMAP2K1CHEK2SLC6A2
SCHEMBL3324238 0.91 IKBKB (0.41) IKBKBCHUKMAP2K1CHEK2SLC6A2
SCHEMBL3325763 0.91 IKBKB (0.41) IKBKBCHUKMAP2K1CHEK2SLC6A2
SCHEMBL3324472 0.89 EED (0.43) IKBKBCHUKMAP2K1CHEK2SLC6A2
SCHEMBL3324465 0.89 EED (0.43) IKBKBCHUKMAP2K1CHEK2SLC6A2
SCHEMBL3325161 0.89 NPY1R (0.42) IKBKBCHUKMAP2K1SLC6A4PIM1
SCHEMBL3325155 0.89 NPY1R (0.42) IKBKBCHUKMAP2K1SLC6A4PIM1
SCHEMBL4238980 0.88 MAP2K1 (0.42) IKBKBCHUKMAP2K1CHEK2SLC6A2
SCHEMBL3325343 0.87 IKBKB (0.44) IKBKBCHUKMAP2K1SLC6A2SLC6A4
SCHEMBL3325337 0.87 IKBKB (0.44) IKBKBCHUKMAP2K1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120858-A1 Piperidine Derivatives PFIZER INC. 2010-05-13 US claimed
EP-2066630-A1 PIPERIDINE DERIVATIVES Pfizer Products Incorporated (US) 2009-06-10 EP claimed
WO-2008023258-A1 PIPERIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-02-28 WO claimed
US-20100120858-A1 Piperidine Derivatives PFIZER INC. 2010-05-13 US disclosed
EP-2066630-A1 PIPERIDINE DERIVATIVES Pfizer Products Incorporated (US) 2009-06-10 EP disclosed
WO-2008023258-A1 PIPERIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120858-A1 Piperidine Derivatives P2RX5, P2RX7, P2RX1 IKBKB 1359/4885CHUK 2338/4885MAP2K1 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.